Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: The CENTERA Study.

Korobelnik, Jean-François; Larsen, Michael; Eter, Nicole; Bailey, Clare; Wolf, Sebastian; Schmelter, Thomas; Allmeier, Helmut; Chaudhary, Varun (2021). Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: The CENTERA Study. American journal of ophthalmology, 227, pp. 106-115. Elsevier Science 10.1016/j.ajo.2021.01.027

[img]
Preview
Text
1-s2.0-S0002939421000581-main.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (696kB) | Preview

PURPOSE

To evaluate the efficacy and safety of intravitreal aflibercept (IVT-AFL) treat-and-extend (T&E) dosing in patients with macular edema secondary to central retinal vein occlusion (CRVO).

DESIGN

CENTERA was an open-label, Phase 4 clinical study.

METHODS

Patients received 2mg IVT-AFL at baseline and every 4 weeks (wks) until disease stability criteria were met (or until Wk20), at which point treatment intervals were adjusted in 2-wk increments based on functional and anatomic outcomes.

RESULTS

From baseline to Wk76, 65.6% (n=105; P<0.0001 [test against threshold of 40%]) of patients gained ≥15 letters; and, during the T&E phase, 45.0% (n=72; P=0.8822 [test against threshold of 50%]) of patients achieved a mean treatment interval ≥8 wks. A last and next planned treatment interval of ≥8 wks was achieved by 63.1% (n=101) and 67.5% (n=108) of patients, respectively. Mean (standard deviation) best-corrected visual acuity increased from 51.9 (16.8) letters at baseline to 72.3 (18.5) letters at Wk76 (mean change: +20.3 [19.5] letters), and central retinal thickness decreased from 759.9 (246.0) µm at baseline to 265.4 (57.9) µm at Wk76 (mean change: -496.1 [252.4] µm). The safety profile of IVT-AFL was consistent with previous studies.

CONCLUSIONS

Clinically meaningful improvements in functional and anatomic outcomes were achieved with IVT-AFL T&E dosing. Most patients achieved a last actual and last intended treatment interval of ≥8 wks, therefore treatment intervals may have been extended even further with a longer study duration.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology

UniBE Contributor:

Wolf, Sebastian

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0002-9394

Publisher:

Elsevier Science

Language:

English

Submitter:

Sebastian Wolf

Date Deposited:

28 Apr 2021 11:05

Last Modified:

08 Jun 2021 01:33

Publisher DOI:

10.1016/j.ajo.2021.01.027

PubMed ID:

33556381

BORIS DOI:

10.48350/153854

URI:

https://boris.unibe.ch/id/eprint/153854

Actions (login required)

Edit item Edit item
Provide Feedback